Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial

Cunningham, D., Stenning, S.P., Smyth, E.C. et al. (15 more authors) (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. The Lancet Oncology, 18 (3). pp. 357-370. ISSN 1470-2045

Metadata

Authors/Creators:
  • Cunningham, D.
  • Stenning, S.P.
  • Smyth, E.C.
  • Okines, A.F.
  • Allum, W.H.
  • Rowley, S.
  • Stevenson, L.
  • Grabsch, H.I.
  • Alderson, D.
  • Crosby, T.
  • Griffin, S.M.
  • Mansoor, W.
  • Coxon, F.Y.
  • Falk, S.J.
  • Darby, S.
  • Sumpter, K.A.
  • Blazeby, J.M.
  • Langley, R.E.
Copyright, Publisher and Additional Information: © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)
Dates:
  • Published (online): 3 February 2017
  • Published: March 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 26 Jul 2017 09:36
Last Modified: 26 Jul 2017 09:36
Published Version: https://doi.org/10.1016/S1470-2045(17)30043-8
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/S1470-2045(17)30043-8

Share / Export

Statistics